Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Chinese Herbal Compound Yijing Keli in the Treatment of Ovarian Aging: A Multicenter and Prospective Study.

NCT06271928 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT06271928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06271928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Chinese Herbal Compound Yijing Keli in the Treatment of Ovarian Aging: A Multicenter and Prospective Study.
Lead sponsor
Tongji Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 1, 2021
Completion date
January 1, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian aging